Food Chemistry, ISSN 0308-8146, 02/2020, Volume 305, p. 125382
During the mashing process for brewing beer, incomplete degradation of arabinoxylan in barley malt may cause an intense filterability problem. The present...
Wort filterability | Aspergillus niger | Glycoside hydrolase | Barley malt | α-l-arabinofuranosidase | FOOD SCIENCE & TECHNOLOGY | STRUCTURAL-ANALYSIS | FILTRATION | alpha-L-arabinofuranosidase | ARABINOXYLAN ARABINOFURANOHYDROLASE | NUTRITION & DIETETICS | FERULIC ACID | FILTERABILITY | CHEMISTRY, APPLIED
Wort filterability | Aspergillus niger | Glycoside hydrolase | Barley malt | α-l-arabinofuranosidase | FOOD SCIENCE & TECHNOLOGY | STRUCTURAL-ANALYSIS | FILTRATION | alpha-L-arabinofuranosidase | ARABINOXYLAN ARABINOFURANOHYDROLASE | NUTRITION & DIETETICS | FERULIC ACID | FILTERABILITY | CHEMISTRY, APPLIED
Journal Article
Inorganic Chemistry, ISSN 0020-1669, 06/2011, Volume 50, Issue 12, pp. 5324 - 5326
A novel water-soluble heptaplatin analogue, cis-[(4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3-dioxolane](3-hydroxy-1,1-cyclobutanedicarboxylato)platinum(II),...
5-FLUOROURACIL | DESIGN | CISPLATIN | ADVANCED GASTRIC-CANCER | DRUGS | ANTICANCER PLATINUM COMPLEXES | COMBINATION | CHEMISTRY, INORGANIC & NUCLEAR | Stereoisomerism | Antineoplastic Agents - chemical synthesis | Humans | Crystallography, X-Ray | Malonates - pharmacology | Structure-Activity Relationship | Organoplatinum Compounds - pharmacology | Dose-Response Relationship, Drug | Malonates - chemistry | Water - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Organoplatinum Compounds - chemistry | Malonates - chemical synthesis | Solubility | Models, Molecular | Survival Rate | Antineoplastic Agents - chemistry | Mice, Inbred ICR | Organoplatinum Compounds - chemical synthesis | Animals | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Drug Screening Assays, Antitumor | Platinum compounds | Analysis | Chemical properties | Structure | Antineoplastic agents | Structure-activity relationships | Antineoplastic antibiotics | Index Medicus
5-FLUOROURACIL | DESIGN | CISPLATIN | ADVANCED GASTRIC-CANCER | DRUGS | ANTICANCER PLATINUM COMPLEXES | COMBINATION | CHEMISTRY, INORGANIC & NUCLEAR | Stereoisomerism | Antineoplastic Agents - chemical synthesis | Humans | Crystallography, X-Ray | Malonates - pharmacology | Structure-Activity Relationship | Organoplatinum Compounds - pharmacology | Dose-Response Relationship, Drug | Malonates - chemistry | Water - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Organoplatinum Compounds - chemistry | Malonates - chemical synthesis | Solubility | Models, Molecular | Survival Rate | Antineoplastic Agents - chemistry | Mice, Inbred ICR | Organoplatinum Compounds - chemical synthesis | Animals | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Drug Screening Assays, Antitumor | Platinum compounds | Analysis | Chemical properties | Structure | Antineoplastic agents | Structure-activity relationships | Antineoplastic antibiotics | Index Medicus
Journal Article
Inorganic Chemistry, ISSN 0020-1669, 07/2010, Volume 49, Issue 13, pp. 5792 - 5794
An unexpected and unusual dimeric platinum(II) tetracarboxylate complex was obtained by the reaction of cis-[Pt(NH3)2I2] with disilver dicarboxylate. The...
Carboplatin - chemistry | Magnetic Resonance Spectroscopy | Antineoplastic Agents - chemical synthesis | Models, Molecular | Crystallography, X-Ray | Lethal Dose 50 | Antineoplastic Agents - chemistry | Spectroscopy, Fourier Transform Infrared | Organoplatinum Compounds - pharmacology | Cyclobutanes - chemical synthesis | Organoplatinum Compounds - chemical synthesis | Animals | Cyclobutanes - pharmacology | Spectrometry, Mass, Fast Atom Bombardment | Cell Line, Tumor | Inhibitory Concentration 50 | Biological Assay | Antineoplastic Agents - pharmacology | Mice | Cyclobutanes - chemistry | Carboplatin - pharmacology | Organoplatinum Compounds - chemistry | Carboplatin | Structure | Chemical properties | Index Medicus
Carboplatin - chemistry | Magnetic Resonance Spectroscopy | Antineoplastic Agents - chemical synthesis | Models, Molecular | Crystallography, X-Ray | Lethal Dose 50 | Antineoplastic Agents - chemistry | Spectroscopy, Fourier Transform Infrared | Organoplatinum Compounds - pharmacology | Cyclobutanes - chemical synthesis | Organoplatinum Compounds - chemical synthesis | Animals | Cyclobutanes - pharmacology | Spectrometry, Mass, Fast Atom Bombardment | Cell Line, Tumor | Inhibitory Concentration 50 | Biological Assay | Antineoplastic Agents - pharmacology | Mice | Cyclobutanes - chemistry | Carboplatin - pharmacology | Organoplatinum Compounds - chemistry | Carboplatin | Structure | Chemical properties | Index Medicus
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 03/2012, Volume 22, Issue 6, p. 2239
Complex 5 is more active and less toxic than its parent compound oxaliplatin.
Journal Article
Journal of Software, ISSN 1796-217X, 2012, Volume 7, Issue 2, pp. 440 - 449
Journal Article
Journal of Inorganic Biochemistry, ISSN 0162-0134, 2008, Volume 102, Issue 10, pp. 1942 - 1946
A series of novel platinum(II) complexes involving a carrier with HO– peripheral functional group, 2-hydroxy-1,3-propanediamine (HO-pda), -[Pt(HO-dpa)X ] (X =...
Synthesis | Anti-tumor | Structure | HO | Platinum complexes | Peripheral functional group | synthesis | anti-tumor | BIOCHEMISTRY & MOLECULAR BIOLOGY | PERSPECTIVES | platinum complexes | AGENTS | peripheral functional group | CYTOTOXICITY | structure | DESIGN STRATEGIES | CARRIER | CHEMISTRY, INORGANIC & NUCLEAR | Cell Survival - drug effects | Antineoplastic Agents - chemical synthesis | Sarcoma 180 - pathology | Drug Resistance, Neoplasm | Male | Cisplatin - pharmacology | Antineoplastic Agents - chemistry | Sarcoma - drug therapy | Organoplatinum Compounds - pharmacology | Sarcoma 180 - drug therapy | Organoplatinum Compounds - chemical synthesis | Animals | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Carboplatin - pharmacology | Platinum - pharmacology | Drug Screening Assays, Antitumor | Organoplatinum Compounds - chemistry
Synthesis | Anti-tumor | Structure | HO | Platinum complexes | Peripheral functional group | synthesis | anti-tumor | BIOCHEMISTRY & MOLECULAR BIOLOGY | PERSPECTIVES | platinum complexes | AGENTS | peripheral functional group | CYTOTOXICITY | structure | DESIGN STRATEGIES | CARRIER | CHEMISTRY, INORGANIC & NUCLEAR | Cell Survival - drug effects | Antineoplastic Agents - chemical synthesis | Sarcoma 180 - pathology | Drug Resistance, Neoplasm | Male | Cisplatin - pharmacology | Antineoplastic Agents - chemistry | Sarcoma - drug therapy | Organoplatinum Compounds - pharmacology | Sarcoma 180 - drug therapy | Organoplatinum Compounds - chemical synthesis | Animals | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Carboplatin - pharmacology | Platinum - pharmacology | Drug Screening Assays, Antitumor | Organoplatinum Compounds - chemistry
Journal Article
Transition Metal Chemistry, ISSN 0340-4285, 5/2011, Volume 36, Issue 4, pp. 337 - 340
A series of mixed-ligand complexes of tris(acetylacetonato) iridium(III) with N-heterocyclic ligands, namely [bis(acac-O,O′)(acac-C3)Ir(L)], where...
Chemistry | Picoline | Physical Chemistry | Tris(acetylacetonato)iridium | Inorganic Chemistry | Catalysis | Crystal structure | N -heterocyclic ligands | N-heterocyclic ligands | IRIDIUM(III) COMPLEXES | Tris(acetylacetonato) iridium | CHEMISTRY, INORGANIC & NUCLEAR
Chemistry | Picoline | Physical Chemistry | Tris(acetylacetonato)iridium | Inorganic Chemistry | Catalysis | Crystal structure | N -heterocyclic ligands | N-heterocyclic ligands | IRIDIUM(III) COMPLEXES | Tris(acetylacetonato) iridium | CHEMISTRY, INORGANIC & NUCLEAR
Journal Article
02/2019
The utility model provides a packaging structure of mattress, including elastic core layer, ventilative cover, vacuum cap and safety cover, the elastic core...
HANDLING THIN OR FILAMENTARY MATERIAL | TRANSPORTING | STORING | CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS,e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES,DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS | CONVEYING | ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR | PACKING | PACKAGING ELEMENTS | PACKAGES | PERFORMING OPERATIONS
HANDLING THIN OR FILAMENTARY MATERIAL | TRANSPORTING | STORING | CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS,e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES,DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS | CONVEYING | ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR | PACKING | PACKAGING ELEMENTS | PACKAGES | PERFORMING OPERATIONS
Patent
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 03/2012, Volume 22, Issue 6, pp. 2239 - 2241
Complex is more active and less toxic than its parent compound oxaliplatin. Six diam(m)ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the...
Synthesis | Platinum | 2,2-bis(Hydroxymethyl)malonate | Anticancer activity | CHEMISTRY, MEDICINAL | ANALOG | CHEMISTRY, ORGANIC | TOXICITY | Magnetic Resonance Spectroscopy | Antineoplastic Agents - chemical synthesis | Humans | Malonates - chemical synthesis | Crystallography, X-Ray | Malonates - pharmacology | Structure-Activity Relationship | Lethal Dose 50 | Mice, Inbred ICR | Organoplatinum Compounds - pharmacology | Animals | Cell Line, Tumor | Coordination Complexes - chemical synthesis | Coordination Complexes - pharmacology | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Mice | Drug Screening Assays, Antitumor
Synthesis | Platinum | 2,2-bis(Hydroxymethyl)malonate | Anticancer activity | CHEMISTRY, MEDICINAL | ANALOG | CHEMISTRY, ORGANIC | TOXICITY | Magnetic Resonance Spectroscopy | Antineoplastic Agents - chemical synthesis | Humans | Malonates - chemical synthesis | Crystallography, X-Ray | Malonates - pharmacology | Structure-Activity Relationship | Lethal Dose 50 | Mice, Inbred ICR | Organoplatinum Compounds - pharmacology | Animals | Cell Line, Tumor | Coordination Complexes - chemical synthesis | Coordination Complexes - pharmacology | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Mice | Drug Screening Assays, Antitumor
Journal Article
Journal of Inorganic Biochemistry, ISSN 0162-0134, 10/2008, Volume 102, Issue 10, p. 1942
A series of novel platinum(II) complexes involving a carrier with HO- peripheral functional group, 2-hydroxy-1,3-propanediamine (HO-pda),...
Care and treatment | Analysis | Hydrogen bonding | Cancer
Care and treatment | Analysis | Hydrogen bonding | Cancer
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 10/2007, Volume 572, Issue 2-3, p. 213
Bis([alpha]-furancarboxylato)oxovanadium(IV) (BFOV) is a new orally active anti-diabetic organic vanadium complex. In the previous studies, we found that BFOV...
Glucose metabolism | Glycogen | Blood sugar | Isoenzymes | Physiological aspects | Knowledge-based systems | Diabetes | Peptide hormones | Sugars | Monosaccharides
Glucose metabolism | Glycogen | Blood sugar | Isoenzymes | Physiological aspects | Knowledge-based systems | Diabetes | Peptide hormones | Sugars | Monosaccharides
Journal Article
Transition Metal Chemistry, ISSN 0340-4285, 05/2011, Volume 36, Issue 4, p. 337
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 2007, Volume 572, Issue 2, pp. 213 - 219
Bis(α-furancarboxylato)oxovanadium(IV) (BFOV) is a new orally active anti-diabetic organic vanadium complex. In the previous studies, we found that BFOV...
Blood glucose | Phosphoenolpyruvate carboxykinase | Insulin | Glucokinase | Fat-fed/streptozotocin rats | Bis(α-furancarboxylato)oxovanadium(IV) | GLUCOSE-6-PHOSPHATASE | blood glucose | insulin | fat-fed/streptozotocin rats | phosphoenolpyruvate carboxykinase | VANADIUM COMPOUNDS | ANTIDIABETIC ACTIVITY | Bis(alpha-furancarboxylato)oxovanadium(IV) | GENE | IN-VIVO | LIVER | PHARMACOLOGY & PHARMACY | glucokinase | TRANSGENIC MICE | Diabetes Mellitus, Experimental - drug therapy | Liver - enzymology | Streptozocin | Kidney - enzymology | Vanadium | Male | Insulin - blood | RNA, Messenger - biosynthesis | Kidney - metabolism | Liver Glycogen - metabolism | Hypoglycemic Agents - administration & dosage | Dietary Fats - administration & dosage | Organometallic Compounds - therapeutic use | Hypoglycemic Agents - therapeutic use | Administration, Oral | Liver - metabolism | Protein-Serine-Threonine Kinases - genetics | Rats | Glucokinase - metabolism | Rats, Sprague-Dawley | Protein-Serine-Threonine Kinases - biosynthesis | Animals | Diabetes Mellitus, Experimental - etiology | Glucose - metabolism | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Organometallic Compounds - administration & dosage
Blood glucose | Phosphoenolpyruvate carboxykinase | Insulin | Glucokinase | Fat-fed/streptozotocin rats | Bis(α-furancarboxylato)oxovanadium(IV) | GLUCOSE-6-PHOSPHATASE | blood glucose | insulin | fat-fed/streptozotocin rats | phosphoenolpyruvate carboxykinase | VANADIUM COMPOUNDS | ANTIDIABETIC ACTIVITY | Bis(alpha-furancarboxylato)oxovanadium(IV) | GENE | IN-VIVO | LIVER | PHARMACOLOGY & PHARMACY | glucokinase | TRANSGENIC MICE | Diabetes Mellitus, Experimental - drug therapy | Liver - enzymology | Streptozocin | Kidney - enzymology | Vanadium | Male | Insulin - blood | RNA, Messenger - biosynthesis | Kidney - metabolism | Liver Glycogen - metabolism | Hypoglycemic Agents - administration & dosage | Dietary Fats - administration & dosage | Organometallic Compounds - therapeutic use | Hypoglycemic Agents - therapeutic use | Administration, Oral | Liver - metabolism | Protein-Serine-Threonine Kinases - genetics | Rats | Glucokinase - metabolism | Rats, Sprague-Dawley | Protein-Serine-Threonine Kinases - biosynthesis | Animals | Diabetes Mellitus, Experimental - etiology | Glucose - metabolism | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Organometallic Compounds - administration & dosage
Journal Article
Guijinshu (Precious Metals), ISSN 1004-0676, 08/2012, Volume 33, Issue 3, pp. 15 - 21
Two hydrosilylation catalysts, cis- and trans-dichlorobis(diethylsulfide) platinum (II), were synthesized and characterized by MS, FT-IR, (1)H and (13)C NMR...
Precious metals | Sulfides | Bright plating | Platinum | Hydrosilylation | Catalysis | NMR spectroscopy | Potassium
Precious metals | Sulfides | Bright plating | Platinum | Hydrosilylation | Catalysis | NMR spectroscopy | Potassium
Journal Article
Journal Article
Platinum Metals Review, ISSN 0032-1400, 2012, Volume 56, Issue 4, pp. 248 - 256
3-Hydroxycarboplatin, a simple carboplatin derivative, was synthesised using a novel method, characterised and evaluated for its anticancer activity in vitro...
ANTICANCER ACTIVITY | SALICYLATE DERIVATIVES | PLATINUM(II) COMPLEXES | ANALOG | CHEMISTRY, PHYSICAL | ANTITUMOR-ACTIVITY | CANCER
ANTICANCER ACTIVITY | SALICYLATE DERIVATIVES | PLATINUM(II) COMPLEXES | ANALOG | CHEMISTRY, PHYSICAL | ANTITUMOR-ACTIVITY | CANCER
Journal Article
Guijinshu (Precious Metals), ISSN 1004-0676, 06/2011, Volume 32, Issue 3, pp. 89 - 96
Platinum complexes are one of the most effective anti-cancer agents currently used in clinical treatments of cancer patients. The past decade has witnessed...
Precious metals | Residues | Capillarity | Mathematical analysis | Platinum | Ignition | Anticancer properties | Cancer
Precious metals | Residues | Capillarity | Mathematical analysis | Platinum | Ignition | Anticancer properties | Cancer
Journal Article
Inorganica Chimica Acta, ISSN 0020-1693, 2007, Volume 360, Issue 8, pp. 2851 - 2856
A series of water-soluble anticancer platinum(II) complexes with an asymmetric chelating diamine 2-morpholinoethylamine as the carrier ligand and with Cl or...
Synthesis | Structure | Anticancer platinum complexes | 2-Morpholinoethylamine | synthesis | anticancer platinum complexes | DESIGN | PERSPECTIVES | 2-morpholinoethylamine | AGENTS | structure | CHEMISTRY, INORGANIC & NUCLEAR
Synthesis | Structure | Anticancer platinum complexes | 2-Morpholinoethylamine | synthesis | anticancer platinum complexes | DESIGN | PERSPECTIVES | 2-morpholinoethylamine | AGENTS | structure | CHEMISTRY, INORGANIC & NUCLEAR
Journal Article
19.
Full Text
cis
Acta Crystallographica Section E, ISSN 1600-5368, 11/2007, Volume 63, Issue 11, p. m2728
In the crystal structure of the title compound, [Pt([C.sub.[6]H.sub.6]O.sub.4)([C.sub.[6]H.sub.7]N).sub.2], the platinum(II) ion is tetracoordinated in a...
Journal Article
Asian Journal of Chemistry, ISSN 0970-7077, 2010, Volume 22, Issue 10, pp. 8174 - 8178
A method for the direct determination of anticancer drug heptaplatin by HPLC has been described. Phenomenex ODS column (150 mm x 4.6 mm i.d., 5 mu m) was used...
Anticancer drug | Heptaplatin | Analysis | HPLC | CHEMISTRY, MULTIDISCIPLINARY
Anticancer drug | Heptaplatin | Analysis | HPLC | CHEMISTRY, MULTIDISCIPLINARY
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.